NYSEAMERICAN:OGEN - Oragenics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.45 +0.04 (+9.76 %)
(As of 09/19/2018 12:20 PM ET)
Previous Close$0.44
Today's Range$0.44 - $0.46
52-Week Range$0.38 - $6.80
Volume1,700 shs
Average Volume511,452 shs
Market Capitalization$105.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:OGEN
CUSIPN/A
Phone+1-813-2867900

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-94.88%

Miscellaneous

EmployeesN/A
Outstanding Shares11,840,000
Market Cap$105.48 million

Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

When did Oragenics' stock split? How did Oragenics' stock split work?

Shares of Oragenics reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

How were Oragenics' earnings last quarter?

Oragenics Inc (NYSEAMERICAN:OGEN) released its earnings results on Monday, August, 13th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.03. View Oragenics' Earnings History.

When is Oragenics' next earnings date?

Oragenics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Oragenics.

Are investors shorting Oragenics?

Oragenics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 877,585 shares, an increase of 13.0% from the August 15th total of 776,521 shares. Based on an average trading volume of 486,169 shares, the short-interest ratio is presently 1.8 days. Currently, 11.0% of the company's stock are short sold. View Oragenics' Current Options Chain.

Who are some of Oragenics' key competitors?

Who are Oragenics' key executives?

Oragenics' management team includes the folowing people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 59)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 62)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 47)
  • Dr. Guojun Nie Ph.D., Director of Process Devel.
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

Has Oragenics been receiving favorable news coverage?

News coverage about OGEN stock has trended somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oragenics earned a news impact score of 0.18 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Oragenics.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.46.

How big of a company is Oragenics?

Oragenics has a market capitalization of $105.48 million.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.


MarketBeat Community Rating for Oragenics (NYSEAMERICAN OGEN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel